Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. [WATCH TIME: 5 minutes]

Gender Disparities in Mood and Quality of Life of Parkinson Disease After DBS: Molly Abbott, BM BCh

Articles

A recent study confirmed ambroxol's safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.

Randomized Trial Highlights Uncertainties of Ambroxol to Improve Cognition in Parkinson Disease Dementia

Indirect treatment comparisons showed significantly greater or statistically higher improvements in MG-ADL scores with nipocalimab versus other FcRn blockers over 24 weeks.

Myasthenia Gravis Medication Nipocalimab Outperforms FcRn Blockers in Indirect Comparison Analysis

West Nile virus poses increasing neurologic risks in the US, with new strains emerging and significant health implications for vulnerable populations.

Concern Over Neuroinvasive Infections Rises as CDC Confirms First US Case of West Nile Virus Lineage 3 

Neuropsychiatry researcher at King's College London.

, has been with the team since September 2022. Follow her on Twitter 

The assistant professor of medicine at Stanford University highlighted how gastrointestinal dysfunction in Parkinson disease can affect levodopa bioavailability and symptom management. [WATCH TIME: 7 minutes]

Gastrointestinal Involvement in Parkinson Disease and Its Impact on Levodopa Efficacy: Laren Becker, MD, PhD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

Laren Becker, MD, PhD, a physician-scientist at Stanford University, discussed how gastrointestinal dysfunction and peripheral dopaminergic activity impact Parkinson disease treatment and progression.

Recognizing Gastrointestinal Symptoms as Early Indicators of Parkinson Disease

Continuous subcutaneous apomorphine infusion significantly reduces OFF episodes and enhances ON time in Parkinson's disease patients, improving overall health status.

Reduction in Parkinson OFF Episodes Through Subcutaneous Apomorphine Infusion Leads to Doubling of Good ON Time

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1.125rem

Clinical

 Parkinson disease Disease Spotlight page gives readers key updates and detailed coverage on the most recent expert conversations and data presentations relevant to the treatment of the movement disorder.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Medcast Podcasts

Optimizing Parkinson's disease (PD) treatment involves leveraging levodopa and adjunct therapies to address both patient-specific and pharmacologic challenges. Effective management requires coordinated care among healthcare providers to ensure comprehensive treatment strategies. Anticipating the impact of emerging therapies and upcoming changes in Medicare Part D is crucial for adapting treatment plans. These changes may influence drug accessibility and affordability, necessitating proactive adjustments in therapeutic approaches. Understanding these dynamics is essential for improving patient outcomes and maintaining the efficacy of PD management strategies.

Stuart Isaacson, MD, Rajesh Pahwa, MD, and Jennifer Goldman, MD discuss optimizing PD treatment with levodopa and adjunct therapies, addressing patient and pharmacologic challenges, coordinating care, and anticipating the impact of emerging therapies and upcoming Medicare Part D changes.

Multisymptomatic Care in Parkinson's Disease

 is now live! Scroll down to listen, and make sure to subscribe on your favorite streaming service.

 features Dr. Anne Marie Morse, DO, a neurologist with special qualifications in child neurology and a sleep medicine specialist, best known for putting the DAMM in 

 and for always looking for digestible, actionable patient-directed sleep tips, tricks and tools to achieve optimal outcomes. Dr. Morse has joined forces with Brandon Hedgecock, DDS, D-ABDSM, a dentist and founder of Hedgecock Dental and 

; and Matthew Allard, AKA the "Sleep Connector," an experienced sleep professional with 20 years of experience helping others sleep and breathe better nightly, to break down the barriers between dentistry and medicine to develop educational content that considers the whole person and illustrate how sleep relates to lifestyle, wellness, and culture.

Sleeping Around the Podcast realized they had more to give and are a partner with 

Sleeping Around the Podcast × NeurologyLive

 for neurology-focused sleep content to allow any neurology stakeholder to add to their knowledge bank and skillset on how to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it is designed to be.

 – Connection between PD and sleep disorders

 – Overview of study assessing biomarker for EDS in Parkinson disease

 – Role of neurofilament light chain in PD

– Patient demographics and differences of NfL increases 

. Check out the links below to subscribe on your preferred podcast platform.

DAMM Good Sleep

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of a newly published study highlighting extracellular vesicle-associated miRNA features that could be diagnostically informative of RBD in patients with Parkinson disease.

Sleeping Around the Podcast × NeurologyLive: Candidate Biomarkers to Detect REM Sleep Behavior Disorder in Parkinson Disease

Watch the video version of this episode here. 

Dyskinesia: Importance of Giving Patients More Good “On- Time" in Parkinson’s Disease

Drs Isaacson, Pahwa, and Gupta discuss the management of dyskinesia and providing good ON time in Parkinson’s disease, sharing practical tips for early identification and treatment of dyskinesia, as well as their experience with current treatments.

 – Sleep disturbances as major feature of PD

 – Parkinson-related pathological changes

Sleeping Around the Podcast × NeurologyLive brings you a scientific overview of the crossover between Parkinson disease and sleep disorders. 

Sleeping Around the Podcast × NeurologyLive: Parkinson Disease Awareness Month

To watch the full video episode, follow this link. 

Widening the Therapeutic Window in the Management of Parkinson’s Disease

Expert neurologists discuss strategies to widen the therapeutic window of Parkinson’s disease and options available to treat dyskinesia, providing better control of Parkinson’s disease.

 to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 93, "Caring for Women With Parkinson Disease," features an exclusive interview with 

, an assistant professor of neurology and director of the Parkinson’s Disease & Movement Disorder Program at Global Neurosciences Institute, who spoke with us about the current landscape of care for women with Parkinson disease (PD), how the approach to their care can differ from men, the major gaps around education and treatment for these women, and much more.

, a streaming channel from MJH Life Sciences

. Check out new content and shows every day, only at

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

FDA Issues Complete Response Letter to Amneal for Parkinson Agent IPX203

FDA Grants Traditional Approval to Lecanemab as Therapy for Early-Stage Alzheimer Disease

Medicare Expands Coverage for Fully Approved Alzheimer Agent Lecanemab

FDA Approves Image Guided Programming Software for Vercise Deep Brain Stimulation Systems

 – The presentation of Parkinson disease for women

 – Nonmotor symptoms that can create challenges  for diagnosis

 – OFF episodes and dyskinesia in women vs men

 – Being attentive to patient needs in treatment

 – The daily impact of Parkinson disease

 – Encouraging women with Parkinson to participate in trials

– Conversations in areas of limited knowledge

 to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jill Farmer, DO, MPH. [LISTEN TIME: 28 minutes]

Episode 93: Caring for Women With Parkinson Disease

 podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 81, "Widening the Therapeutic Window in Parkinson Disease," features an exclusive interview with Robert A. Hauser, MD, MBA, director of the Parkinson’s and Movement Disorders Center at the University of South Florida. He spoke about the current state of therapeutics in Parkinson disease, some of the lingering challenges in day-to-day management, the promise of novel agents in development such as IPX203, and more.

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. 

Neurelis Files IND for Potentially First Therapy to Treat Cerebral Cavernous Malformations

CDC and FDA Announce Stroke Safety Concern Related to Pfizer-BioNTech Bivalent COVID-19 Vaccine

FDA Hands Eli Lilly Complete Response Letter for Donanemab After Lack of Long-Term Data

FDA Clears Trial Hold on Late-Onset Pompe Disease Gene Therapy AT845

Proclaim XR Spinal Cord Stimulation Wins Approval for Painful Diabetic Peripheral Neuropathy

 – Lingering unmet needs in Parkinson disease management

 – The advances in identifying therapeutic targets in PD

 – Bridging the gap to more effective long-term treatment

 – Overview of IPX203 and its potential to treat PD

 – Safety profile of IPX203 in clinical development

 – The importance of addressing dose-wearing off

 podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Robert A. Hauser, MD, MBA. [LISTEN TIME: 20 minutes]

Episode 81: Widening the Therapeutic Window in Parkinson Disease

Episode 78, "A Virtual Reality Platform for Parkison Disease," features an exclusive interview with Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic. He joined the show to discuss the complexities that come with understanding early signs of PD, and how the newly designed Cleveland Clinic Virtual Reality Shopping (CC-VRS) platform works towards that, among other topics.

. Check out new episodes of a variety of shows, airing every single day, only on

International Committee Proposes MS Disease Progression Framework Driven by Pathophysiological Mechanisms, Not Clinical Phenotype

Anti-Amyloid-ß Oligomer Antibody ACU193 Gains FDA Fast Track Designation

Duchenne Gene Therapy SRP-9001 Wins Priority Review

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Episode Breakdown

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jay Alberts, PhD. [LISTEN TIME: 27 minutes]

Episode 78: A Virtual Reality Platform for Parkinson Disease

Exablate Neuro is a noninvasive, MRI-guided focused ultrasound technology designed to treat targeted brain areas without incisions or implanted hardware, offering a lower-risk alternative to traditional surgery.

Exablate Neuro Gains FDA Approval for Staged Bilateral Focused Ultrasound in Advanced Parkinson Disease 

Research reveals that delayed-release amantadine significantly reduces Parkinson disease symptoms and medication use, offering patients improved quality of life.

Switch From Amantadine Immediate-Release to Gocovri Results in Improved Real-World Parkinson Disease Benefits

A physician assistant specializing in Parkinson disease shared key clinical considerations for selecting and educating patients about on-demand therapies for the movement disorder.

NeuroVoices: Cheryl Kyinn, PA-C, on Personalizing On-Demand Therapies for OFF Episodes in Parkinson Disease

The neuropsychiatry researcher at King's College London highlighted significant gender differences in anxiety, depression, quality of life, and social support among patients with PD undergoing deep brain stimulation. 

"This work’s important because we know that anxiety and depression affect up to half of our patients [with Parkinson disease]. Yet we don’t know whether this prevalence is replicated within a deep brain stimulation cohort (DBS), nor whether the same gender differences that we see in the general Parkinson population are replicated in a DBS cohort."

Moods such as anxiety and depression impact between 40% to 50% of patients living with Parkinson disease (PD), with studies showing a higher prevalence in women.

 Research has also shown that fewer women with PD have undergone deep brain stimulation (DBS) surgery because of reduced patient preference, increased depression, reduced clinician referrals.

 In a recent study of a DBS cohort, findings revealed that women with PD were disproportionately underrepresented and had a reduced quality of life, with significantly reduced preoperative social support.

These results were presented as an awarded poster at the recently concluded 4th Annual 

Advanced Therapeutics in Movement and Related Disorders (ATMRD) Congress

 from June 27-30, 2025. Presented by lead author Molly Abbott, BM BCh, resident doctor and neuropsychiatry researcher at King's College London, the findings from the study support the practice of tailored DBS counselling by gender, particularly considering reducing social support in women. The belief is that a type of study like this may provide momentum for additional research into the reasons underpinning the gender difference in PD symptoms, and the barriers to women recruitment for DBS.

To explore the broader implications of this study, Abbott sat down with

 to discuss the intersection of gender, mood, and quality of life in patients with PD undergoing DBS. In the conversation, she touched on key themes from the study such as patient representation, pre- and postoperative experiences, and how these insights may shape future approaches to care. Overall, Abbott’s reflections during the interview emphasized the importance of considering gender-specific factors when assessing outcomes and counseling patients ahead of DBS surgery.

Click here for more coverage of ATMRD 2025

REFERENCES
1. Jost ST, Strobel L, Rizos A, et al. Gender gap in deep brain stimulation for Parkinson's disease. NPJ Parkinsons Dis. 2022;8(1):47. Published 2022 Apr 20. doi:10.1038/s41531-022-00305-y
2. Cerri S, Mus L, Blandini F. Parkinson's Disease in Women and Men: What's the Difference?. J Parkinsons Dis. 2019;9(3):501-515. doi:10.3233/JPD-191683
3. Shpiner DS, Di Luca DG, Cajigas I, et al. Gender Disparities in Deep Brain Stimulation for Parkinson's Disease. Neuromodulation. 2019;22(4):484-488. doi:10.1111/ner.12973
4. Abbott M, Ahmed A, Okai D, et al. Gender Differences in Depression, Anxiety and Quality of Life in Parkinson’s Disease Before and After Deep Brain Stimulation Surgery: A Multicenter Cohort Study. Presented at: ATMRD; June 27-30, 2025; Washington, DC. P-53

SAP Partners

At ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. 

Sharing Treatment Strategies for Patients With Parkinson Disease Beyond Medication: Esther Labib-Kiyarash, MSHA, CPHQ

"Getting a therapist for me post-diagnosis was an absolute lifesaver. It should be something that’s very routine because it’s trauma. It’s a traumatic experience and it’s a family disease. It didn’t just impact me—it impacted my children, my husband, everybody that loves me and that I love."

At ATMRD 2025, a patient advocate living with PD and advisory board member of the Parkinson's Foundation outlined key nonpharmacologic tools that have supported her care journey. [WATCH TIME: 5 minutes]

Parkinson Disease

Latest News